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Vegf signaling specifies arterial fate during early
vascular development by inducing the transcription
of Delta-like 4 (Dll4), the earliest Notch ligand gene
expressed in arterial precursor cells. Dll4 expression
precedes that of Notch receptors in arteries, and
factors that direct its arterial-specific expression
are not known. To identify the transcriptional pro-
gram that initiates arterial Dll4 expression, we char-
acterized an arterial-specific and Vegf-responsive
enhancer of Dll4. Our findings demonstrate that
Notch signaling is not required for initiation of Dll4
expression in arteries and suggest that Notch
instead functions as a maintenance factor. Impor-
tantly, we find that Vegf signaling activates MAP
kinase (MAPK)-dependent E26 transformation-spe-
cific sequence (ETS) factors in the arterial endothe-
lium to drive expression of Dll4 and Notch4. These
findings identify a Vegf/MAPK-dependent transcrip-
tional pathway that specifies arterial identity by acti-
vating Notch signaling components and illustrate
how signaling cascades can modulate broadly ex-
pressed transcription factors to achieve tissue-spe-
cific transcriptional outputs.
INTRODUCTION
Arterial and venous blood vessels are anatomically, functionally,
and molecularly distinct. Establishing and maintaining these
separate endothelial cell fates is critical to the proper function
of circulatory networks in the embryo and the mature adult
(Marchuk, 1998). Angioblasts are specified in the lateral plate
mesoderm during gastrulation. Bilateral streaks of vascularDendothelial growth factor receptor 2 (VEGFR2)/Flk1+-preaortic
angioblasts, or arterial precursor cells (aPCs), form the dorsal
aortae, followed by the formation of the embryonic veins by a
distinct group of angioblasts (Chong et al., 2011). Arteriovenous
(AV) specification is genetically determined before hemody-
namic forces come into play. Hedgehog (Hh) signaling induces
expression of Vegf in a dorsal to ventral gradient in the early
embryo (Lawson et al., 2002). Arterial cells are thought to receive
a higher concentration of Vegf, which activates p42/p44 MAPK
signaling (Hong et al., 2006) and induces the expression and acti-
vation of Notch signaling pathway components exclusively in the
arterial endothelium (Lawson et al., 2002). Once activated, the
intracellular domain of the cleaved Notch receptor (NICD) inter-
acts with its transcriptional cofactor, RBPJk, in the nucleus to
induce expression of Hey1/2, Hes1, EphrinB2 (Efnb2), and other
downstream arterial genes (Yamamizu et al., 2010). The molec-
ular events following Notch activation that maintain arterial iden-
tity are well understood (Swift andWeinstein, 2009), yet the initial
transcriptional cues that function downstream of Vegf activation
to induce the expression of Notch signaling components are
unknown.
Dll4 is the first Notch ligand gene expressed in the arterial
endothelium (Chong et al., 2011), and its expression is induced
by Vegf (Lawson et al., 2001). Expression of Dll4 is initiated in
the dorsal aorta before genes encoding its cognate receptors,
Notch1 and Notch4, making Dll4 one of the earliest markers of
the arterial lineage (Chong et al., 2011). Significantly, loss of
only one copy of Dll4 produces AV specification defects and
embryonic lethality in mice (Duarte et al., 2004; Gale et al.,
2004; Krebs et al., 2004). Defining the transcriptional program
responsible for early Dll4 expression will therefore provide key
insights into arterial specification.
We describe the isolation of an arterial-specific enhancer
of Dll4, which labels aPCs and differentiated arterial cells. We
find that this enhancer is responsive to Vegf/MAPK signaling,
and, through deletion analysis, we identify a previously unap-
preciated role for ETS transcription factors in mediating theevelopmental Cell 26, 45–58, July 15, 2013 ª2013 Elsevier Inc. 45
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Figure 1. Identification of an Intronic Enhancer of Dll4 that Drives Arterial-Specific Expression
(A) Conservation between murine and opossumDll4with location of fragment 1 (F1) and F2 indicated. Transgenic analysis of F1-lacZ and F2-hsp68-lacZ (E9.5) is
below. Further analysis of F1-lacZ is shown in Figures S1A and S1B.
(B) In situ hybridization of endogenous Dll4 (top) and expression in Dll4lacZ/+ (middle) and a stable Dll4-F2-hps68-lacZ (F2) reporter line (bottom). Dorsal aorta
(arrows).
(legend continued on next page)
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ETS Factors Regulate Arterial SpecificationVegf-responsiveness and arterial-specificity of this enhancer
and endogenous Dll4. This Vegf/MAPK/ETS pathway also regu-
lates the expression of Notch4, which encodes an arterial-
specific receptor of Dll4. These studies provide mechanistic
insight into the transcriptional program downstream of the Vegf
receptor that mediates arterial specification through the induc-
tion of Notch signaling components.
RESULTS
The Genomic Region 50 of Dll4 Does Not Drive Arterial-
Specific Expression
To understand the transcriptional basis of AV specification, we
searched for evolutionarily conserved noncoding regions
(ECRs) of the Dll4 locus. The region proximal to the Dll4
transcriptional start-site is regulated by b-catenin signaling
through TCF/LEF sites and can also be activated by FOXC1/2
and RBPJk in vitro (Caolo et al., 2010; Corada et al., 2010;
Seo et al., 2006). We cloned this 5-kb region (fragment 1, F1)
and placed it upstream of a promoterless b-galactosidase re-
porter (Figure 1A; see also Figure S1A available online). The
activity of this reporter construct was tested in transient trans-
genic mouse embryos, where it failed to direct any arterial
expression (Figures 1A, S1A, and S1B). This suggests that
this region is not sufficient to mediate the arterial-specific
expression of Dll4.
Wnt Signaling Is Not Required for Early Dll4 Expression
or Artery Specification
Endothelial-specific deletion of Ctnnb1, the gene encoding
b-catenin, results in embryonic lethality at E12.5 (Cattelino
et al., 2003). However, whether AV specification occurs nor-
mally in Ctnnb1 loss-of-function mice has not been pre-
viously assessed. Overexpression of a dominant-active allele
of Ctnnb1 induces Dll4 expression (Corada et al., 2010), lead-
ing to the suggestion that Wnt/b-catenin plays an instructive
role in arterial specification by inducing Notch signaling.
However, we were unable to detect active canonical Wnt
signaling in the arterial endothelium at E8.5 or E9.5 using multi-
ple established Wnt reporter lines (BAT-gal, Axin2-d2EGFP,
Axin2lacZ) (Figures S1C–S1E). To determine if Wnt signaling
regulates early Dll4 expression, we ablated Ctnnb1 specifically
in the endothelium. The dorsal aortae and cardinal vein were
morphologically normal at E8.5 (data not shown) and E9.5
(Figure S1F), expression of Dll4 mRNA was unchanged (Fig-
ure S1G), and we did not observe any arteriovenous mal-
formations (AVMs) in Ctnnb1 mutants at E9.5 (Figure S1H).
Collectively, these results demonstrate that Wnt/b-catenin
signaling in the endothelium is dispensable for early artery for-
mation and early Dll4 expression and that the DNA region up-
stream of the promoter of Dll4 is not sufficient for artery-specific
expression.(C) F2 expression in early arterial precursors (aPCs) and in cardiac crescent (CC
(D) Transverse sections of F2 expression. DA, dorsal aorta (arrow); CV, cardinal
(E) A stable Dll4-F2-E1b:GFP transgenic zebrafish line demonstrates arterial-spe
CVP, caudal vein plexus; ISV, intersomitic vessel; DLAV, dorsal longitudinal anas
(F) Cross-section of axial vasculature of F2:GFP zebrafish. PCV, posterior cardin
See also Figure S1.
DIdentification of a Dll4 Enhancer with Activity in the
Developing Arterial Endothelium and Endocardium
Another well-conserved ECR (fragment 2, F2) is located within
the third intron of Dll4 (Figure 1A). This region can respond to
FOXN4 (Luo et al., 2012), RBPJk/NICD, and b-catenin (Yama-
mizu et al., 2010) in both ex-vivo and in vitro reporter analyses,
but its in vivo activity has not been assessed. In transient trans-
genic embryos, F2 drove robust activation of a minimal pro-
moter-lacZ reporter (hsp68-lacZ) in the arterial endothelium and
endocardium, similar to endogenous Dll4 mRNA expression
and to the b-galactosidase activity of Dll4lacZ/+ embryos (Fig-
ure 1B). Analysis of embryos at E7.5–E7.75 from multiple stable
transgenic founder lines demonstrated that this enhancer labeled
aPCs prior to their coalescence into the cord-like structures of
the dorsal aorta (Figures 1B and 1C). Examination of transverse
sections confirmed the arterial-specificity of the enhancer from
E8.5 through E10.5 (Figure 1D). F2 also drove strong expression
in the endocardium, another tissuewhereDll4mRNA is observed
(Figure 1B), suggesting that this enhancer recapitulates the entire
developmental endothelial expression pattern of endogenous
Dll4. F2, like endogenous Dll4, was active in the arteries of the
postnatal retina, but it was not active in the vasculature of the
adult retina, suggesting that F2 is a developmentally regulated
enhancer (data not shown). To determine whether this en-
hancer’s functionality was conserved in other vertebrate species,
we injected an F2:GFP transgene into zebrafish embryos and es-
tablished stable transgenic lines. Expression of GFPwas specific
to the dorsal aorta, cardinal artery, and intersomitic vessels, with
very little expression detectable in the posterior cardinal vein or
caudal vein plexus (Figures 1E and 1F). This intronic Dll4 F2
element is therefore a bona fide arterial-specific enhancer.
A 36 bp Fragment Necessary and Sufficient for
Arterial-Specific Enhancer Activity Is Regulated by ETS
and RBPJk
Comparative genomic analysis revealed that the full-length F2
enhancer contains regions of high conservation among distantly
related mammals (Figure 2A). Using deletion analyses of the
802 bp F2 enhancer, we identified a 350 bp (F2-2) and a
225 bp fragment (F2-4) that both labeled the arterial endothe-
lium, as well as a weak endocardial enhancer (F2-3) that failed
to label the arterial endothelium in mice (Figures 2A and 2B).
The proximal 176 bp of the F2 enhancer (F2-5), which is con-
tained in F2 and F2-2, but absent in F2-4, was not sufficient to
drive arterial expression (Figures 2A and 2B). F2, F2-2, and
F2-4 share a common 100 bp region that, when deleted in
the context of the entire 802 bp enhancer (F2D1), abolished
arterial activity (Figures 2A and 2B). A well-conserved 36 bp
element within this common region was necessary (F2D2) and,
when concatamerized head-to-tail in triplicate (F2-6(3X)), was
sufficient to direct arterial and endocardial expression (Figures
2A–2C). Further characterization revealed that this minimal). NT, neural tube.
vein (caret).
cific expression. kdrl:ras-mCherry marks all blood vessels. CA, caudal artery;
tomotic vessel.
al vein. Scale bars represent 500 mm (B), 100 mm (D), 50 mm (E), and 10 mm (F).
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Figure 2. Isolation of a Minimal Dll4 Enhancer Element that Drives Arterial-Specific Expression
(A) Sequence conservation of the F2 enhancer and deletion constructs used in transgenic analyses. Endocardial and arterial expression is indicated.
(B) Representative transgenic embryos from (A) at E9.5. F2, F2-2, and F2-4 directed strong arterial-specific expression. F2-3 directed weak endocardial (EC)
expression. Deletion of a highly conserved 100 bp and 36 bp region (F2D1 and F2D2, respectively) abrogated arterial activity of the F2 enhancer. The 36 bp region,
F2-6, was sufficient, when arrayed in triplicate, F2-6(3X), to direct arterial expression. DA, dorsal aorta; AA, aortic arch; LB, limb bud; NT, neural tube; ICA, internal
cerebral artery; HT, heart. Scale bar represents 500 mm.
(C) Transverse section of X-gal stained F2-6(3X)-lacZ embryo at E9.5. DA (arrow); cardinal vein (caret); EC (double arrow). Scale bar represents 100 mm.
(D) Whole-mount image of F2-6(3X)-lacZ embryo at E8.5. Scale bar represents 500 mm.
(legend continued on next page)
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ETS Factors Regulate Arterial Specification36 bp enhancer (F2-6(3X)) was capable of directing robust and
reproducible arterial expression at early stages (i.e., E8.5) of
vascular development (Figure 2D). Importantly, transient trans-
genesis revealed that this 36 bp enhancer was also able to drive
strong arterial-specific expression in the dorsal aorta and inter-
somitic vessels (Figure 2E), as well as the endocardium (data
not shown), of zebrafish embryos. Venous expression was not
observed in embryonic mice or zebrafish (Figures 2C and 2E).
The minimal enhancer contains conserved predicted binding
sites for ETS, MEF2, E2F, and RBPJk transcription factors (Fig-
ure 2F). We testedwhich sites were required for activity in vivo by
separately mutating each DNA-binding site in the context of the
F2-6(3X):GFP reporter and performing transient transgenesis
assays in embryonic zebrafish. At 24 hr postfertilization (hpf),
75% of embryos injected with the wild-type F2-6(3X) enhancer
displayed arterial expression of GFP. Mutation of the E2F
element did not affect enhancer activity, but mutation of the
MEF2 element resulted in a modest, but significant reduction
in arterial expression (Figure 2G). In mice, Mef2a and Mef2c
are expressed within the endothelium (Lin et al., 1998; Wang
et al., 2003) and loss of Mef2c leads to early embryonic lethality
(E9.5) and produces a range of vascular defects, including an
absent or disorganized dorsal aorta (Bi et al., 1999; Lin et al.,
1998). Although recombinant MEF2C protein bound to the
MEF2 site of F2-6(3X) (Figure S2A), MEF2C was not required
for either F2 activity or endogenous Dll4 expression (Figures
S2B and S2C). Conversely, only 5% of zebrafish embryos in-
jected with an ETS mutant F2-6(3X):GFP construct had arterial
expression and mutation of the RBPJk-binding site abolished
arterial expression (Figure 2G). These results suggest that ETS
and RBPJk play a critical role in regulating F2-6(3X) enhancer ac-
tivity in vivo and imply that they may regulate endogenous Dll4.
Neither the RBPJk Site in the F2 Full-Length Enhancer
nor Notch Signaling Are Required for Initiation of Dll4
Expression
It has been proposed that activated Notch signaling can induce
Dll4 gene expression via RBPJk-mediated transcriptional regula-
tion through a feed-forwardmechanism (Caolo et al., 2010).Given
that the activity of the minimal F2-6(3X) enhancer was dependent
upon a putative RBPJk-binding site, we sought to determine if
Notch signaling is necessary or sufficient to regulate the activity
of the full-length F2enhancer. Forced inductionofNotch signaling
throughout the vasculature promotes the arterialization of veins
(Krebs et al., 2010). Indeed, endothelial-specific overexpression
of the intracellular domain of Notch1 produced AVMs in mouse
embryos and expanded F2 reporter activity into the venous endo-
thelium (Figure S2D), suggesting that the enhancer is Notch
responsive. However, although RBPJk bound to the F2 enhancer
(Figure S2E), mutation of the RBPJk site in the context of the full-
length F2 enhancer failed to diminish arterial-specific expression(E) Mosaic expression of F2-6(3x):GFP in the DA and intersomitic vessels (ISVs) o
Scale bar represents 50 mm.
(F) Sequence comparison of F2-6 in human (Hs), mouse (Mm), opossum (Md), c
(G) Each cis element was mutated in F2-6(3X):GFP and transient transgenics we
expression in arteries (i.e., DA and/or ISV), expression elsewhere, and no exp
expression compared to wild-type (c2 test).
See also Figure S2.
Din transient transgenesis analyses in zebrafish ormice (Figures 3A
and3B).Wenext assessedwhetherNotchsignaling is required for
F2 enhancer activity. Rbpjk knockdown in zebrafish reduced late
(i.e., 26 hpf), but not early (i.e., 20 somites) enhancer activity (Fig-
ure 3C), consistent with a role for Notch signaling in the mainte-
nance, but not the establishment of arterialDll4 enhancer activity.
Inmice, global lossofRbpjk, which leads to defects in somitogen-
esis and neural tube formation (Oka et al., 1995), diminished but
failed to abolish F2 reporter activity at E8.25 or E8.5 (Figure 3D).
Additionally, in embryos where Rbpjk was ablated specifically in
the endothelium—bypassing global morphogenetic defects—
the activity of the F2 reporter was unaffected at E8.5 or E9.5 (Fig-
ure 3E), demonstrating that RBPJk does not play a cell-autono-
mous role in initiating Dll4 enhancer activity. Finally, Dll4 mRNA
was only moderately reduced in Rbpjk/ mice compared to
wild-type littermates at E8.5 (Figure 3F). Together, these results
indicate that Notch signaling is not required for the early arterial
expression of Dll4, but is essential for its maintenance.
ETS Factors Regulate the Activity of the Dll4 Enhancer
ClustalW analysis revealed the presence of nine perfectly
conserved minimal ETS elements (ETS sites A–G), including
the site within F2-6(3X) (ETS-B) (Figure S3A). This was intriguing
because several ETS family members are key regulators of
endothelial development (De Val and Black, 2009). EMSA
confirmed that six of these sites competed for binding of the
ETS1 DNA binding domain (DBD) to a known ETS element (Fig-
ure S3B). Among these six sites, ETS-B is present in all arterial-
positive constructs (F2, F2-2, F2-4, and F2-6) and corresponds
to a canonical ETS-1 binding site (cETS-1). ETS-B also directly
and specifically bound recombinant ETS1-DBD (Figure S3C)
and ETV2, an ETS family member (Figure S3D).
To determine the functional requirement of the ETS binding
sites in vivo, we generated transient transgenic zebrafish
harboring the full-length F2 enhancer driving GFP in which
ETS-B or all six of the ETS1 DBD-binding ETS sites were
mutated. Mutation of the six ETS binding sites abolished F2
enhancer activity, and mutation of the ETS-B site alone severely
reduced enhancer activity in arteries (Figure 4A); confirming the
importance of this single ETS element. Given the necessity of
ETS binding sites for enhancer activity, we wondered whether
ETS factors were sufficient to induce Dll4 expression. Thus, we
next determinedwhether overexpression of ETS factors was suf-
ficient to induce expression of endogenous DLL4 in human
umbilical vein endothelial cells (HUVEC), a venous cell type
that expresses low levels of DLL4. Indeed, overexpression of
two different endothelial-enriched ETS family members, ETV2
or ERG, induced endogenous DLL4 expression (Figure 4B).
Induction of DLL4 was accompanied by binding of V5-ERG
to the endogenous region of DLL4 corresponding to F2 (i.e.,
intron 3), but not to a distal region of theDLL4 locus, as assessedf a transient transgenic 30 hpf zebrafish embryo. PCV, posterior cardinal vein.
hicken (Gg), and zebrafish (Dr). Cis elements are indicated.
re assessed for arterial expression at 24 hpf. The percentage of embryos with
ression, are indicated. Asterisk indicates a significant difference in arterial
evelopmental Cell 26, 45–58, July 15, 2013 ª2013 Elsevier Inc. 49
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Figure 3. Notch Signaling Is Not Required
for Early Arterial Expression of Dll4
(A) Transient transgenesis of wild-type F2:GFP
compared to a RBPJk mutant construct
(F2DRBPJk:GFP). DA, dorsal aorta; PCV, posterior
cardinal vein; ISV, intersomitic vessel.
(B) Whole-mount images (left), and transverse
sections (right) of wild-type and RBPJk-mutated
F2-lacZ transgenic embryos.
(C) Expression of F2:GFP in control and rbpjk
morphant (MO) embryos, demonstrating normal
enhancer activity in the DA (arrow) at 20 somites,
but decreased expression at 26 hpf. Expression of
kdrl:GFP in the DA was unaffected.
(D) F2-lacZ expression was reduced but present
in the DA of Rpbjk/ embryos at E8.5 (Rpbjk+/+,
n = 25;Rpbjk/, n = 5) and E8.25 (Rpbjk+/+, n = 14;
Rpbjk/, n = 4).
(E) F2-lacZ expression was normal at E8.5 (left),
and at E9.5 in whole-mount (center) and trans-
verse sections (right) from embryos with endo-
thelial cell-specific loss (ECKO) of Rbpjk, although
mutants had a reduced DA diameter (bar) at E9.5,
as previously reported (Krebs et al., 2004). E9.5,
Rpbjkdel/fl, n = 6; RpbjkECKO, n = 4; E8.5, Rpbjkdel/fl,
n = 8; RpbjkECKO, n = 3.
(F) In situ hybridization shows that Rbpjk is not
absolutely required for Dll4 expression at E8.5
(n = 3 for each genotype). DA, arrows; asterisk,
neural tube. Scale bars represent 50 mm (A and C),
500 mm for whole-mounts, and 100 mm for sections
(B and D–F).
See also Figure S2.
Developmental Cell
ETS Factors Regulate Arterial Specificationby chromatin immunoprecipitation (ChIP) (Figure 4C). Further-
more, we detected high levels of endogenous ERG occupancy
at intron 3, but not a distal site in the Dll4 locus, in an arterial
cell line (bovine aortic endothelial cells [BAECs]) (Figure 4D). By
comparison, NICD was only modestly enriched at intron 3 in
BAECs (Figure 4D). Collectively, these results demonstrate that
ETS factors can induce expression of endogenous DLL4
mRNA and that ETS factors directly occupy the endogenous
DLL4 genomic region corresponding to F2 in arterial cells.
To further define the role of ETS factors in the regulation ofDll4
expression, we performed loss- and gain-of-function experi-50 Developmental Cell 26, 45–58, July 15, 2013 ª2013 Elsevier Inc.ments in mouse and zebrafish. Fli1a
and Erg are closely related ETS factors
that play redundant roles in regulating
angiogenesis during zebrafish vascular
development (Liu and Patient, 2008).
Combined morpholino knockdown of
these two ETS factors decreased
F2:GFP expression at both early and
late stages of vascular development (Fig-
ure 4E), and endogenous dll4, efnb2a,
and hey2 expression were also dimin-
ished (Figure 4F). However, kdrl:GFP
expression (a pan-endothelial marker)
was unaffected (Figure 4E), as was kdr
mRNA (Figure 4F). Conversely, injection
of ERGmRNA increased F2:GFP expres-sion within the dorsal aorta and in what appeared to be the form-
ing posterior cardinal vein at early stages of arterial specification
(i.e., 20 somite stage), and also promoted premature sprouting of
intersomitic vessels (Figure S4A). However, expanded enhancer
activity in the vein was not observed at later stages of vascular
development (i.e., 24 hpf; not shown). Because Notch target
genes (i.e., efnb2a, hey2) were decreased in erg/fli1amorphants,
we assessed Notch transcriptional activity using a Notch re-
porter line (Tp1:GFP) (Parsons et al., 2009) in an erg/fli1a loss-
of-function setting. Strong Tp1:GFP expression in the dorsal
aorta and intersomitic vessels was observed in 94% of control
Developmental Cell
ETS Factors Regulate Arterial Specificationembryos (n = 83) compared to only 67% of erg/fli1a morphants
(n = 165), suggesting that arterial Notch signaling was compro-
mised in a proportion of ETS morphants (Figure 4G).
Erg splice variants in mice, driven from a translational start site
in Exon 4, are specifically expressed in the endothelium, and Erg
Exon 4 null mouse embryos (ErgDEx4/DEx4) die early in develop-
ment (E10.5–E11.5) with severe vascular remodeling defects in
the yolk sac and impaired vascularization of the central nervous
system (Vijayaraj et al., 2012). We found that the dorsal aortae
formed normally in ErgDEx4/DEx4 embryos (Figure S4B), but Dll4
expression was modestly reduced at E8.5 (Figure 4H) and sub-
stantially downregulated at E9.5 (Figure 4I), confirming a role
for this ETS family member in regulating Dll4 mRNA expression.
Interestingly, several other arterial markers were also reduced in
ErgDEx4/DEx4 embryos at E8.5 (Figure 4H), and levels of Efnb2
were modestly reduced at E8.5 (Figures 4H and S4C) and E9.5
(Figure 4J), but were severely altered at E10.5 (data not shown).
However, we did not find evidence of gross morphological AVM
defects in ErgDEx4/DEx4 embryos at E9.5 (Figures S4B and S4D)
and only rarely observed shunts in erg/fli1a morphant zebrafish
embryos (data not shown). We take these results to indicate
that ETS factor redundancy may functionally compensate for
the loss of ERG or Erg/Fli1a within the endothelium. Together
these data define a role for ETS factors in the regulation of the
arterial-specific expression of Dll4 and indicate that ETS factors
are involved in the specification of arterial fate.
Vegf Signaling Regulates the Expression of Dll4 through
the Induction and Activation of ETS Factors
Arterial specification is largely Hh- and Vegf-dependent (Lawson
et al., 2002; Vokes et al., 2004), and Dll4 expression is regulated
by Vegf levels (Coultas et al., 2010; Liu et al., 2003). We therefore
assessed whether F2 enhancer activity was Vegf-responsive.
vegfa knockdown in zebrafish dramatically reduced F2 arterial
enhancer activity (Figures 5A and 5B), similar to endogenous
dll4mRNA (Figure 5C). However, the expression of a pan-endo-
thelial marker (kdrl:GFP) in the axial vessels and levels of kdr and
kdrl mRNA were largely unaffected (Figures 5A–5C), confirming
that vegfa does not regulate vasculogenesis in zebrafish. Global
overexpression of Vegfa, achieved by coinjection of mRNAs
encoding Vegfa121 and Vegfa165, dramatically increased F2
activity in arterial cells (Figure 5D). In addition, F2 activity was
expanded into the vein, confirming that Vegf levels regulate the
arterial-specific expression of Dll4. Additionally, we examined
F2-lacZ activity in two mutant mouse backgrounds that affect
Vegf signaling. Hh-mediated activation of Smoothened (SMO)
is required for expression of Vegf in the rostral somites at E8.5
and loss of Smo leads to disorganized or collapsed anterior
(but not posterior) dorsal aortae by E8.5; although Flk1+ cells
are specified and present in normal numbers (Vokes et al.,
2004). Significantly, Smo mutants have reduced Dll4 mRNA in
the anterior, but not posterior, dorsal aorta at E8.5 (Coultas
et al., 2010). Correspondingly, we found that F2 enhancer activity
was reduced in the anterior, but not the posterior dorsal aorta
of Smo mutants at E8.25, and activity was abolished in this
region of the dorsal aorta by E8.5 (Figure S5A). Additionally,
enhancer activity was absent in Vegfr2/ embryos (Figure S5A),
although this is likely the result of reduced vasculogenesis (Sha-
laby et al., 1995).DTo determine which cis elements within F2 mediate this Vegf
responsiveness, we performed luciferase assays in cultured
arterial endothelial cells treated with VEGF or the VEGF receptor
inhibitor, SU5416. Endogenous DLL4 mRNA was elevated in
cells treated with VEGF compared to cells treated with SU5416
(Figure 5E). Although wild-type F2-luciferase activity was
enhanced upon VEGF-treatment, mutation of ETS-B abrogated
Vegf responsiveness and this reduction was only slightly more
pronounced in the ETS-6xmutant (Figure 5F). Althoughmutation
of the RBPJk site modestly reduced enhancer activity, this
reduction was not as severe as mutation of the ETS elements.
This suggests that the Vegf responsiveness of the Dll4 enhancer
is largely ETS-dependent.
Control of ETS activity by Vegf signaling could be mediated by
alterations in the expression and/or activity of ETS factors. We
first assessed whether the recruitment of ETS factors to the
enhancer at the endogenous DLL4 locus was dependent on
Vegf signaling. RNA Polymerase II occupancy at the DLL4
enhancer in cultured arterial cells was enhanced in VEGF-treated
cells compared to cells treated with VEGF inhibitor (Figure 5G), a
finding consistent with transcriptional regulation of DLL4. Impor-
tantly, ERG occupancy of the enhancer was also increased in the
presence of Vegf signaling (Figure 5G). However, Vegf treatment
did not alter ERG protein levels (Figure 5H), or ERG subcellular
localization in arterial cells (Figures 5I and S5B). Interestingly,
ERG protein levels were elevated in lysates from cells of arterial
origin (human umbilical artery endothelial cells [HUAEC]) com-
pared to corresponding venous cells (HUVEC) (Figure 5J), and
expression of ERG was moderately enriched in the dorsal aorta
compared to the cardinal vein in vivo (Figure S5C), suggesting
that ERG is enriched in arterial cells. Although ERG levels were
not affected by short-term inhibition of Vegf signaling in cultured
arterial cells, the expression of several ETS factors are Vegf-
responsive in vitro (Ghosh et al., 2012; Heo et al., 2010). There-
fore, we examined the levels of endothelial-enriched ETS factors
(Liu and Patient, 2008) to determine whether Vegf regulated their
expression during vascular development. Compared to controls,
quantitative RT-PCR (qRT-PCR) analyses revealed that levels of
elf2a, elf2b, elk4, erg, ets1a, and fli1a were significantly reduced
in vegfa morphants (Figures S5D and S5E). In contrast, the
expression of etv2, which acts early in the gastrulation-stage
mesoderm to specify endothelial cells (Lee et al., 2008), was un-
affected by Vegf inhibition (Figures S5D and S5E). Thus, expres-
sion of several endothelial ETS factors is modulated by Vegf
signaling in vivo, and their decreased expression coincides
with a reduction in dll4 expression.
To determine if ETS factors function downstream of Vegf sig-
naling to induceDll4 expression, we overexpressed ERG in vegfa
morphants. Coinjection of ERG mRNA partially rescued Dll4 F2
enhancer activity, sprouting of ISVs, and endogenous dll4
expression in vegfamorphant embryos (Figures6Aand6B). Inter-
estingly, F2 enhancer activity was expanded into the vein in ERG
overexpressing vegfamorphants. Conversely, knockdown of erg
and fli1a (using a subphenotypic dose of morpholino) prevented
the Vegf-mediated induction of F2:GFP in both the artery and
the vein (Figure 6C). Increased expression of endogenous dll4
(Figure 6D) and efnb2a (Figure S6A) induced by Vegf overexpres-
sion was also blunted in erg/fli1amorphants. Collectively, our re-
sults show that Vegf regulates ETS factors in arterial endothelialevelopmental Cell 26, 45–58, July 15, 2013 ª2013 Elsevier Inc. 51
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Figure 4. Dll4 Is Regulated by ETS Factors
(A) Representative images (left) and quantification (right) of wild-type, ETS-B, and ETS-6x mutant F2:GFP embryos at 48 hpf. ISV, intersomitic vessel; DA, dorsal
aorta; PCV, posterior cardinal vein. Asterisk indicates a significant difference in arterial expression compared to wild-type (c2 test).
(B) Expression of endogenous DLL4 in HUVEC electroporated with ETV2 or ERG expression constructs (n = 3, ETV2; n = 5, ERG).
(C) V5-ERG expression in electroporated HUVEC (left). ChIP in V5-ERG-electroporated HUVEC. Fold enrichment (V5 versus IgG) was measured at the Dll4
enhancer (intron 3) and Dll4 exon 11 (n = 2).
(D) ChIP in BAEC for RNA Polymerase II (RNA Pol II), ERG or the Notch intracellular domain (NICD) (n = 3). Asterisk indicates significant enrichment over IgG
control.
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Figure 5. Vegf Regulates the Dll4 Enhancer
through an ETS Element
(A) Expression of F2:GFP (arterial) and kdrl:GFP
(pan-endothelial) in control or vegfa morphant
embryos. Lateral dorsal aorta (arrows); dorsal
aorta (DA). Scale bar represents 50 mm.
(B) Quantification of GFP intensity in the DA (n R
10 per group).
(C) Expression (qRT-PCR) of dll4 (arterial), kdr, and
kdrl (pan-endothelial) in control and vegfa mor-
phant embryos (nR 3 per group).
(D) Overexpression of Vegfa enhanced expression
of F2:GFP in arterial cells and expanded expres-
sion to venous cells. CA, caudal artery; CVP,
caudal vein plexus. Quantification is shown (n = 6–
8 embryos per group). Scale bar represents 50 mm.
(E) Expression of DLL4 (qRT-PCR) in BAECs
treated with VEGF or VEGF receptor inhibitor
(SU5416) for 24 hr (n = 3).
(F) Relative F2:luciferase activity in BAEC treated
with VEGF or SU5416. A representative experi-
ment with three technical replicates is shown.
Asterisk indicates a significant difference in lucif-
erase activity compared to all other constructs.
Number sign (#) indicates a significant difference
between RBPJk MT and ETS-B MT, 6x-ETS MT
and RBPJk/ETS-B MT.
(G) ChIP assays for RNA Pol II and ERG in BAEC
treated with VEGF or SU5416 for 24 hr (n = 3).
(H) Western blotting demonstrating equal expres-
sion of ERG protein in BAECs treated with VEGF or
SU5416 for 24 hr.
(I) Intracellular localization of ERG was unchanged
by VEGF treatment. Scale bar represents 20 mm.
(J) Expression of ERG was elevated in arterial cells
(HUAEC) compared to venous cells (HUVEC). All
graphical data are mean ± SEM.
See also Figure S5.
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ETS Factors Regulate Arterial Specificationcells by inducing their expression and recruitment to DNA. Vegf-
regulated ETS factors in turn control F2 enhancer activity, endog-
enous Dll4 expression and contribute to arterial specification.
The Vegf/MAPK Pathway Activates an Arterial
Transcriptional Program through Activation of ETS
Factors
Vegf-mediated activation of the p42/p44 MAPK and PI3K
signaling pathways are known to promote or antagonize arterial(E) Expression of F2:GFP (arterial) and kdrl:GFP (pan-endothelial) in erg;fli1a morphants. Representative ima
(F) Endogenous dll4, ephrinb2a, hey2, and kdr in control and erg;fli1a morphants assessed by qPCR (n = 5–
(G) Notch activity (Tp1:GFP) was diminished in the dorsal aorta of 30% of erg/fli1a morphants.
(H) Levels of arterial markers and a pan-endothelial marker (Pecam1) were quantified by qRT-PCR in E8.5 e
embryos).
(I) Endogenous Dll4 mRNA is downregulated in the DA of ErgDEx4/ DEx4 embryos (arrows; n = 3 embryos per
(J) Efnb2 section in situ hybridization at 9.5 shows downregulation of Efnb2 in the DA (arrows) of ErgDEx4/ DEx
bars represent 50 mm (A, E, and G), 500 mm (I), 100 mm (J). All graphical data are mean ± SEM.
See also Figures S3 and S4.
Developmental Cell 26, 4specification, respectively (Deng et al.,
2013; Hong et al., 2006; Ren et al.,
2010). Pharmacological inhibition of
p42/p44 MAPK signaling in arterial cells
in vitro decreased DLL4 expression (Fig-ure 7A). An arterial-enriched Notch receptor gene, NOTCH4,
was also reduced, but NOTCH1 and venous gene expression
(EPHB4 and COUP-TFII), were unchanged (Figure 7A). Consis-
tent with decreased Notch ligand (i.e., DLL4) and receptor (i.e.,
NOTCH4) levels, expression of a Notch-activated transcription
factor gene, HES1, and a Notch-dependent arterial marker,
EFNB2, were also reduced (Figure 7A). These data suggest
that MAPK signaling is required for the maintenance of Notch
signaling in arterial endothelium. In contrast, inhibition of PI3Kges (left) and quantification (n = 5–10) (right).
10 individual embryos).
mbryos (n = 3 for wild-type, n = 2 for ErgDEx4/ DEx4
genotype) at E9.5.
4 embryos (Erg+/+, n = 3; ErgDEx4/ DEx4 n = 2). Scale
5–58, July 15, 2013 ª2013 Elsevier Inc. 53
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Figure 6. ETS Factors Act Downstream of
Vegf to Induce dll4 Expression
(A) ERGmRNA (200 pg) injection partially rescued
F2:GFP expression and sprouting (arrows) in
vegfa morphants at 26 hpf. Representative
images (left) and quantification (right, n = 10–12).
(B) dll4 mRNA expression (normalized to kdr
expression) was assessed by qRT-PCR in indi-
vidual 26 hpf embryos injected with ERG mRNA
and/or vegfa morpholino (n = 4).
(C) Partial knockdown of erg and fli1a with a sub-
phenotypic dose of morpholino inhibited the in-
duction of F2:GFP expression in both the dorsal
aorta (DA) and posterior cardinal vein (PCV) in
Vegfa121/165 mRNA-injected embryos. Arrows
indicate collapsed PCV. Quantification of 10–13
embryos per group is shown.
(D) Endogenous dll4 mRNA was assessed by
qRT-PCR in individual embryos at 24 hpf (n = 5).
All graphical data are mean ± SEM.
See also Figure S6A.
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ETS Factors Regulate Arterial Specificationactivity with the small molecule, LY29004, enhanced expression
ofDLL4,NOTCH4,HES1, and EFNB2 (data not shown). Because
NOTCH4 was regulated similarly to DLL4, we examined ECRs
within the NOTCH4 locus for conserved ETS elements. An
ECR within intron 1 of NOTCH4 contained multiple conserved
ETS sites, and this region had high ERG occupancy in arterial
cells, as assessed by ChIP (Figure 7B). Overexpression of ERG
in HUVEC induced NOTCH4 mRNA, suggesting that NOTCH4
is an ETS factor-regulated gene (Figure 7C). Similar to DLL4,
NOTCH4 expression was downregulated upon Vegf inhibition
(Figure 7D), and this was accompanied by a decrease in ERG
recruitment to intron 1 (Figure 7E). We also found that ERG
recruitment to DLL4 intron 3 and NOTCH4 intron 1 was reduced
in cells treated with a MAPK inhibitor (Figure 7F), suggesting that
ERG recruitment to these enhancers is MAPK-dependent.
Accordingly, Vegf-induced Dll4 F2-luciferase activity was sup-
pressed by MAPK inhibition in arterial cells and mutation of the
ETS-B site largely abrogated this responsiveness (Figure 7G).
In contrast, inhibition of PI3K signaling enhanced Vegf-induction
of F2-luciferase activity, and this was also dependent on the
ETS-B site (Figure S6B), suggesting that PI3K inhibition may
enhance ETS activity. To determine whether MAPK regulates
Dll4 in vivo, we inhibited MAPK signaling beginning at the 10-
somite stage and found a significant decrease in F2:GFP expres-
sion at 28 hpf (Figures S6C and S6D). Expression of endogenous
dll4 and hey2 mRNA was also reduced, whereas efnb2a levels
were modestly decreased (Figure S6E). However, kdrl:GFP and
kdr expression were unaffected (Figures S6D and S6E). In agree-
ment with the MAPK inhibitor data, overexpression of dominant
activeMEKK in endothelial cells resulted in ectopic expression of
F2:GFP within venous cells in vivo (Figure S6F), implying a cell-54 Developmental Cell 26, 45–58, July 15, 2013 ª2013 Elsevier Inc.autonomous role for MAPK signaling in
the regulation of arterial Dll4 expression.
DISCUSSION
Hh/Vegf-dependent activation of Dll4
expression and Notch/RBPJk activity isa prerequisite for early artery specification and maintenance in
the developing vertebrate embryo (Swift and Weinstein, 2009).
The MAPK pathway activates the arterial program downstream
of VEGFR2, whereas PI3K signaling antagonizes the MAPK
pathway and arterial fate (Deng et al., 2013; Hong et al., 2006;
Ren et al., 2010). However, the transcriptional mediators that
are activated downstream of VEGFR2/MAPK and induce Dll4
expression, and hence Notch activation, remain unknown.
Here, we report the identification of an arterial-specific enhancer
(F2) of Dll4, one of the earliest markers of the coalescing aPCs
that form the dorsal aortae. The activity of the Dll4 F2 enhancer
described here recapitulates endogenous Dll4 expression in
the arterial and endocardial endothelium of the developing em-
bryo. Functional analysis of this enhancer reveals that a minimal
36 bp DNA element, when concatenated, can drive arterial-spe-
cific expression, and through systematic mutation of the cis ele-
ments in this enhancer, we identify a role for the ETS family of
transcription factors in the Vegf- and MAPK-dependent initiation
ofDll4 expression (Figure 7H). Critically,Notch4 is also regulated
by this Vegf/MAPK/ETS pathway, suggesting that this genetic
networkmay coordinately activate expression of Notch signaling
components to initiate Notch signaling in the early artery.
Previous work implicated FOXC1/2 and b-catenin in the regu-
lation of Dll4 expression (Corada et al., 2010; Seo et al., 2006;
Yamamizu et al., 2010). However, our results argue against these
factors directing the arterial-specific expression of Dll4. In the
case of Foxc1/2-dependent regulation of Dll4, the conclusions
rely largely upon the phenotype of Foxc1/;Foxc2/ mice,
which have AVMs and reduced arterial gene expression. How-
ever, these embryos also completely lack somites 1–8 at E8.5
(Seo et al., 2006), which are a critical source of Hh-induced
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Figure 7. Vegf/MAPK Signaling Activates
Arterial Genes by Promoting ETS Factor
Binding
(A) Expression of arterial genes (DLL4, NOTCH4,
EFNB2) and the Notch target gene, HES1, were
decreased in VEGF-treated BAEC cotreated with
the MAPK inhibitor, U0126 (n = 4). NOTCH1 and
vein markers were unaffected.
(B) An ECR (human reference genome) present in
intron 1 of NOTCH4 contains multiple conserved
ETS elements and binds ERG, as assessed by
ChIP assay (n = 6).
(C) Overexpression of ERG in HUVEC increased
NOTCH4 expression by qRT-PCR (n = 4).
(D) Inhibition of Vegf signaling decreased NOTCH4
expression, but had no effect on NOTCH1 (n = 3).
(E) Inhibition of Vegf signaling decreased ERG
binding to intron 1 of NOTCH4 (n = 5).
(F) Inhibition of MAPK signaling decreased ERG
binding to DLL4 intron 3 and NOTCH1 intron 1
(n = 3).
(G) Inhibition of MAPK decreased F2:luciferase
activity and mutation of the ETS-B site similarly
decreased activity and abrogated MAPK-respon-
siveness. Shown is a representative experiment,
triplicate determinations.
(H) Model of Dll4 regulation during artery devel-
opment. At early stages of vasculogenesis (left),
ETV2 is expressed independent of Vegf signaling
in angioblasts and activates the Dll4 enhancer.
At later stages of development, activity of other
ETS factors, such as ERG are induced down-
stream of Vegf/MAPK signaling in the arterial
precursor cells (aPCs) (middle), and expression
of Dll4 and Notch4 is activated. Once Dll4 and
Notch receptors are both expressed, continued
Notch signaling maintains Dll4 enhancer activity
and activates and maintains the expression of
other arterial genes (right). All graphical data are
mean ± SEM.
See also Figure S6.
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ETS Factors Regulate Arterial SpecificationVegf that is required for artery specification (Coultas et al., 2010).
Similarly, although prior studies suggested that canonical Wnt/
b-catenin signaling is active in early arteries (i.e., E9.5) and b-cat-
enin drivesDll4 promoter activity (Corada et al., 2010), we find no
evidence of active canonical Wnt/b-catenin signaling in early
arteries (i.e., E8.5 and E9.5) and Dll4 expression in the dorsal
aorta is intact when Ctnnb1 is deleted from the endothelium,
suggesting that b-catenin is dispensable for early artery specifi-
cation. Finally, the genomic fragment that is located just up-
stream of Dll4—where b-catenin/TCF/LEF and Foxc1/2 have
been suggested to function—does not direct arterial-specific
expression.
Vegf-mediated activation of Notch signaling, via NICD/RBPJk
transcriptional activity is necessary and sufficient to induce
downstream transcription factors, such as Hey2 and other arte-
rial markers, such as Efnb2 (Swift and Weinstein, 2009). How-
ever, we postulate that Notch signaling is not required for the
initiation ofDll4 expression and primitive dorsal aortae formation.
Dll4 is the first Notch ligand expressed in the forming arteries in
the mouse, and Dll4 expression (first detected at E8.0) precedesDthat of the genes encoding arterial Notch receptors, Notch1 and
Notch4 (detected at E8.25) (Chong et al., 2011); calling into ques-
tion how endothelial cell-autonomous Notch signaling could
initiate Dll4 expression. Indeed, Notch1/;Notch4/ mice
have normal levels of Dll4 at E9.5 (albeit in an abnormal expres-
sion pattern), and the dorsal aortae are still formed (Krebs et al.,
2000). Similarly, dorsal aortae are present when Rbpjk is deleted
specifically in the endothelium (Krebs et al., 2004). Although
the arterial enhancer of Dll4 that we isolated (F2) contains a
conserved functional binding site for RBPJk, we provide several
lines of evidence demonstrating that Notch signaling is not
required for the initial arterial expression of Dll4. First, mutation
of the RBPJk site in the context of the full-length enhancer
does not affect its arterial-specificity in mice or zebrafish
embryos. Second, global loss of Rbpjk in embryonic mice or
zebrafish fails to abolish enhancer activity early in arterial devel-
opment. Third, early arterial expression of endogenous Dll4
mRNA is present, albeit at reduced levels, in Rbpjk/ embryos.
However, endothelial-specific ablation of Notch signaling does
not diminish F2 activity at E8.5 or E9.5, suggesting a possibleevelopmental Cell 26, 45–58, July 15, 2013 ª2013 Elsevier Inc. 55
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estingly, Dll4 enhancer activity in the dorsal aorta is greatly
reduced in later-stage rbpjk morphant zebrafish embryos, sug-
gesting that Notch signaling maintains Dll4 expression. Collec-
tively, our findings demonstrate that initiation of Dll4 expression
during artery specification is Notch-independent. We propose
that Dll4 expression is initiated during vasculogenesis (through
Notch-independent mechanisms; see below), and that Notch
signaling subsequently becomes activated by a Vegf/MAPK/
ETS pathway that regulates both Dll4 and Notch4 (Figure 7H).
Subsequently, Dll4 expression is maintained through a Notch-
dependent positive feedback loop to sustain artery specification,
as has been previously suggested (Caolo et al., 2010).
A highly conserved ETS site (i.e., ETS-B) is responsible for the
majority of the activity of the arterial enhancer of Dll4, including
its responsiveness to Vegf/MAPK signaling. How then do ETS
factors, many of which are uniformly expressed in the vascula-
ture, regulate the arterial specificity of Dll4? The Dll4 enhancer
can be bound (Figure S3D) and activated (data not shown) by
the angioblast-enriched ETS family member ETV2 (Lee et al.,
2008). Interestingly, the first angioblasts to arise during murine
development appear to be arterial (Chong et al., 2011). We there-
fore posit that ETV2 initiates Dll4 expression during vasculogen-
esis (Figure 7H). Our data further suggests that a second wave of
Vegf-dependent ETS factors appears to reinforce Dll4 expres-
sion in the forming dorsal aortae (Figure 7H). We find that Vegf
regulates the expression of several zebrafish ETS factors in the
endothelium, including elf2a, elf2b, elk4, erg, ets1, and fli1a.
Furthermore, ERG appears to be enriched in arterial cells,
implying that some ETS factors may be arterial-enriched. More
importantly, we discover that the recruitment of ERG to the
Dll4 F2 enhancer and an ECR within Notch4 is induced by
Vegf/MAPK signaling. In this case, differential ERG occupancy
is not mediated by changes in total ERG levels or subcellular
localization, suggesting that Vegf/MAPK signaling enhances
the DNA binding activity of ERG. We have also observed Vegf-
dependent recruitment of ETS1 to these same enhancers
(unpublished results mined from data in Zhang et al., 2013), sug-
gesting that additional ETS family members may be regulated
similarly to ERG, and cooperatively control arterial specification.
Importantly, the enhanced activation of the Dll4 enhancer and
endogenous dll4 in response to vegfa overexpression can be
attenuated by knockdown of erg and fli1a, suggesting that ETS
factors are necessary for the Vegf-induced expression of Dll4.
We also find reduced Dll4 expression in the dorsal aorta of
ErgDEx4/DEx4 mice and in erg/fli1a morphant zebrafish embryos,
but failed to observe AVMs, suggesting that other ETS factors
compensate in the specification of the early artery.
Vegf is known to selectively activateMAPK signaling in arteries
compared to veins during embryogenesis (Corson et al., 2003;
Hong et al., 2006). Interestingly, several ETS family members
are phosphorylated by MAPKs (Hill et al., 1993; Murakami
et al., 2011; Petrovic et al., 2003), and these modifications are
known to affect their interaction with other transcription factors
as well as their binding to DNA (Hollenhorst et al., 2011). Future
experiments will examine ETS factor phosphorylation down-
stream of Vegf/MAPK signaling and whether ETS factors
functionally interact with other transcription factor families to
establish arterial fate. Finally, we also demonstrate that a Vegf/56 Developmental Cell 26, 45–58, July 15, 2013 ª2013 Elsevier Inc.MAPK/ETS pathway regulates Notch4, suggesting that this
pathway lies upstream of induction of Notch signaling in the
arterial endothelium. Indeed, we observe reduced Notch-regu-
lated gene expression and Notch-dependent reporter activity
in embryos with reduced ETS activity. Interestingly, Notch4 is
not as sensitive as Dll4 to ERG overexpression (Figure 4B versus
Figure 7C), whichmay in part explain the delay inNotch4 expres-
sion during artery formation (Chong et al., 2011).
In summary, we have uncovered a genetic pathway that inte-
grates Vegf signaling, ETS-dependent transcriptional regulation,
and the induction of one of the earliest, essential ligands for
artery specification and Notch pathway activation, Dll4. This
same pathway also regulates the expression of Notch4, an
arterial-specific receptor for Dll4, and appears to initiate Notch
signaling in the artery. These findings may provide insight into
congenital defects in AV specification andmaintenance and sug-
gest approaches to direct endothelial cells toward the arterial
lineage.
EXPERIMENTAL PROCEDURES
Bioinformatic Analyses, Cloning, Mutagenesis, Generation of
Transgenic Mice, and Mouse Lines Used
See Supplemental Experimental Procedures for details.
Mouse Experiments
All mouse protocols were approved by the Institutional Animal Care and Use
Committee at UCSF and Harvard Medical School. Histology and in situ hybrid-
ization (Dodou et al., 2003; Wythe et al., 2011), ink injections (Krebs et al.,
2004), and CD31 immunofluorescence (Coultas et al., 2010) were performed
as described elsewhere.
Electrophoretic Mobility Shift Assay
DNA binding assays were performed as described previously (Dodou et al.,
2003). See Supplemental Experimental Procedures for details.
Cell Culture, Immunofluorescence, Luciferase Analysis, and ChIP
Human umbilical vein endothelial cells (HUVECs) (ScienCell) and Bovine
arterial endothelial cells (BAECs) (Lonza) were grown in endothelial media
(ScienCell). BAECs were treated with 50 ng/ml recombinant Vegf-A165 (R&D
Systems), 0.5 mM SU5416 (Sigma), 20 mM U0126 (Invivogen), or 10 mM
LY29004 (Cell Signaling) for 24 hr. Immunofluorescence of ERG and
phalloidin was performed as described (Fish et al., 2011) using ERG antibody
(Santa Cruz, C-20, 1:100 dilution). pCS2-6xMYC-Etv2 (De Val et al., 2008)
has been described and pCMV-Sport6-ERG was from Open Biosystems
(IMAGE clone 6052140). Cloning of pCS2-V5-ERG is described in Supple-
mental Experimental Procedures. Luciferase experiments were performed
as described (Cheng et al., 2013). Electroporation of HUVEC was performed
using a Lonza 4D Nucleofector with the P5 Primary Cell Kit with 2.5 mg of
expression construct and 0.5 mg of pmaxGFP. ChIP was performed using
the Imprint Kit (Sigma) with 1 mg of antibody: RNA Pol II (mouse monoclonal,
Sigma), ERG (rabbit polyclonal, Santa Cruz, C-20), V5 (mouse monoclonal,
Invitrogen), or NICD (rabbit polyclonal, ChIP grade, Abcam). IgG (mouse,
Sigma) was used as a negative control. Fold enrichment was calculated
by determining the fold change of qPCR values for the specific antibody
compared to IgG control. See Supplemental Experimental Procedures for
primer sequences.
Zebrafish Experiments
Zebrafish protocols were approved by the Animal Care Committee at the
University Health Network and UCSF. The following transgenic lines were
utilized: Tg(kdrl:ras-mCherry)s896 (Chi et al., 2008), Tg(kdrl:GFP)s843 (Jin et al.,
2005), and Tg(EPV.Tp1-MmuHbb:EGFP)um14 (Parsons et al., 2009). See Sup-
plemental Experimental Procedures for generation of Tg(Dll4-F2-E1b:GFP)
and experimental details.
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qRT-PCR was performed as before (Fish et al., 2008). See Supplemental
Experimental Procedures for details and primer sequences.
Western Blot
Western blotting was performed as described previously (Fish et al., 2011)
using ERG (rabbit polyclonal, Santa Cruz, C-20), Sin3a (Santa Cruz, AK-11),
V5 (mouse monoclonal, Invitrogen), or GAPDH (mouse monoclonal, Santa
Cruz) (mouse monoclonal, Abcam) antibodies. Cells were starved overnight
and treated with 50 ng/ml recombinant Vegf-A165 (R&D Systems) for 20 min
before harvesting for subcellular fractionation, as previously described (Wythe
et al., 2011). HUVEC and HUAEC lysates were purchased from Sciencell.
Statistics
All graphs depict the mean ± SEM of at least three independent experiments
unless otherwise indicated. Statistical significance was performed using a
Student’s t test, ANOVA, or c2 test as appropriate.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.devcel.2013.06.007.
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